Trumbull, Connecticut, October 10, 2022 (Globe Newswire) – ZetrOZ . systemsInnovative and manufacturer sam® wearable ultrasound machine product line, continues to expand its clinical education program on the benefits of continuous acoustic medicine for soft tissue healing, use of pain relief therapy and obtain health insurance coverage for a pain relief device.
Sustainable Acoustic Medicine (SAM®) is the only in-house biomedical device approved by the FDA for the treatment of specific medical indications, most commonly for chronic joint pain in the shoulder, knee, and elbow, and for the treatment of overuse injuries. Over 50 clinical and scientific studies support its effectiveness in treating injuries, restoring function, and returning patients to work and daily activities.
said Dr. George Lewis, founder and CEO of ZetrOZ Systems. “This technology delivers results without the need for opioids or other medications while treating patients and their recovery is up to 40% faster than standard methodologies.”
Clinical education on SAM® is directed by Dr. Rod Walters and Dr. Rajiv Malibudi. Walters is a nationally recognized leader in athletic training with decades of experience at major universities and as a consultant to clients including the National Football League, Big 12 Athletic Conference and Cirque du Soleil. He was inducted into the National Athletic Coaches Association Hall of Fame in 2005.
Dr. Malibody, MD, MHS, a board-certified internal medicine hospital physician and assistant professor at Yale University School of Medicine in New Haven, Connecticut. He is a clinical researcher active in improving health care quality, with study projects for ways to reduce length of stay for hospital patients and to improve patient outcomes.
Walters and Malibody share a common goal of educating physicians, physical therapists, and athletic trainers about the benefits and use of the SAM® device, in hopes of reducing the need for surgeries and pain medications and improving the likelihood of patients returning to work, sports, and normal daily activities. By providing clinical training resources, including online videos, medical professionals now have information on best practices for drug-free, non-invasive treatment of patient injuries.
Adherence to the SAM® system throughout the repair phase provides a necessary and safe intervention to ensure that patients avoid recurrent chronic injuries. Recommended practices are outlined in the educational materials and include:
- SAM treatment can be applied with one or two ultrasound stimuli.
- The SAM® device should be used at least four times a week.
- Treatments should be applied gradually to assess patients’ response to treatment, from an initial treatment of one hour to a maximum of four hours per treatment.
- For acute cases, the duration of treatment can range from 4 to 8 weeks.
- For chronic cases, treatment can range from 2 to 12 weeks.
Clinical education directs clinicians that SAM® can serve as a stand-alone treatment or can be used to supplement other treatment approaches to stimulate soft tissue repair and that its value as a treatment option that does not require surgery or pain relief medications.
SAM® Therapy is also a cost-effective treatment option. For example, a 2020 study on osteoarthritis of the knee was published in the journal Journal of Orthopedics and ResearchSAM® was found to provide a greater improvement in functional efficacy per dollar of care than standard care options.
ZetrOZ Systems continues to provide education on sam® technology, and most recently participated in the 2022 SPHEM (Association of Professional Hockey Equipment Managers) PHATS (Association of Professional Hockey Equipment Managers) conference in June. The results demonstrated that SAM® is a non-invasive, non-narcotic alternative for pain, and that the ease of use of the device led athletes to return to normal activity after treatment.
To find out more, visit zetrozsystems.com.
About ZetrOZ أنظمة Systems
ZetrOZ Systems is leading therapeutic innovations in sports medicine, developing wearable bioelectronic devices to deliver sustainable acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on over 46 patented medical technology and is the exclusive manufacturer and developer of sam®, a product line designed to treat acute and chronic musculoskeletal conditions. To find out more, visit zetrozsystems.com.
This content was released by Newswire.com’s press release distribution service.